Dallas, Texas
Phase 1 colorectal cancer trials in Dallas, TX
30 Phase 1 colorectal cancer studies are recruiting participants at sites in Dallas as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Dallas at a glance
- 30 studies are recruiting at a site in Dallas.
- By phase: Phase 1 (16), Phase 1/2 (14).
- By sponsor: industry (29), university, hospital or other (1).
- Most recent update to one of these records: November 17, 2026.
Studies recruiting in Dallas
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Phase 1/2 Study of IAM1363 in HER2 Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study site
- Mary Crowley Cancer Research
- Registry record
- NCT06253871 · updated
A Study of VET3-TGI in Patients With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- KaliVir Immunotherapeutics
- Study site
- Mary Crowley Cancer Research/Sarah Cannon Research Institute
- Registry record
- NCT06444815 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Texas Oncology - DFW (Sammons CC)
- Registry record
- NCT07213791 · updated
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Sairopa B.V.
- Study site
- University of Texas Southwestern Medical Center
- Registry record
- NCT05856981 · updated
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- START Dallas Fort Worth
- Registry record
- NCT07542704 · updated
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Genmab
- Study site
- Texas Oncology
- Registry record
- NCT03526835 · updated
Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Phase 1/2
- Ages 18 to 90
- All sexes
- Sponsor
- Perspective Therapeutics
- Study site
- UT Southwestern University Hospital Radiology Clinic
- Registry record
- NCT06710756 · updated
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- Phase 1/2
- Ages 18 to 80
- All sexes
- Sponsor
- Blue Earth Diagnostics
- Study site
- University of Texas Southwestern Medical Center
- Registry record
- NCT07432633 · updated
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Daiichi Sankyo
- Study site
- Texas Oncology, P.A.
- Registry record
- NCT06330064 · updated
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study sites
- Mary Crowley Cancer Research · University of Texas Southwestern
- Registry record
- NCT04657068 · updated
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kura Oncology, Inc.
- Study site
- UT Southwestern Simmons Cancer Center
- Registry record
- NCT06026410 · updated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- PMV Pharmaceuticals, Inc
- Study site
- UT Southwest Simmons Cancer Center
- Registry record
- NCT04585750 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #89
- Registry record
- NCT05176483 · updated
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Study sites
- SCRI at Mary Crowley · University of Texas Southwestern Medical Center
- Registry record
- NCT06625775 · updated
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT07277270 · updated
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Neonc Technologies, Inc.
- Study site
- Baylor, Scott and White Research Institute
- Registry record
- NCT06047379 · updated
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- NEXT - Dallas
- Registry record
- NCT07349537 · updated
A Study of ASP1002 in Adults for Treatment of Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Mary Crowley Cancer Research Center
- Registry record
- NCT05719558 · updated
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pilatus Biosciences Inc
- Study site
- NEXT Dallas
- Registry record
- NCT07337525 · updated
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Recursion Pharmaceuticals Inc.
- Study site
- Genetic Cancer Prevention Clinic - UT Southwestern
- Registry record
- NCT05552755 · updated
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Sarah Cannon Research Institute at Mary Crowley
- Registry record
- NCT06040541 · updated
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Study site
- Sarah Cannon Research Institute at Mary Crowley
- Registry record
- NCT06917079 · updated
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- Turning Point Therapeutics, Inc.
- Study site
- UT Southwestern Medical Center
- Registry record
- NCT03093116 · updated
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Mary Crowley Cancer Research
- Registry record
- NCT05379985 · updated
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Tasca Therapeutics
- Study site
- NEXT Oncology - Dallas
- Registry record
- NCT07030257 · updated
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Clasp Therapeutics, Inc.
- Study sites
- Baylor University Medical Center · Mary Crowley Cancer Research
- Registry record
- NCT06778863 · updated
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Auricula Biosciences Inc.
- Study site
- NEXT Oncology Dallas
- Registry record
- NCT07148128 · updated
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Study site
- NEXT Dallas
- Registry record
- NCT07317505 · updated
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- LigaChem Biosciences, Inc.
- Study site
- Mary Crowley Cancer Research
- Registry record
- NCT05941507 · updated
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
- Study site
- NEXT Oncology, Dallas
- Registry record
- NCT05746897 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Dallas, TX on ClinicalTrials.gov.
Ask about studies near Dallas
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Texas
All Texas locations
119 studies recruiting across 18 cities.
Houston
86 studies recruiting.
San Antonio
43 studies recruiting.
Irving
15 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections